Valeant Pharmaceuticals International, Inc. (VRX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aegis Capital Comments on Valeant Pharma (VRX) Following Q1 Results
May 8, 2014 9:46 AM EDTAegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following Q1 results. Valeant reported Q1 EPS of $1.76,versus consensus views calling for EPS of $1.72. Revenue for the quarter came in at $1.85 billion, versus $1.04 billion reported last year.
Analyst Ram Selvaraju commented, We have slightly modified... More
